CCR2 and neoplasm: The rather late application of the depleting mAb for only a limited time is certainly a suboptimal experimental setup to evaluate the therapeutic efficacy of combining tumor vaccination with the depletion of CCR2+ cells, as we only observe minute effects on survival (Figure 6E) and a transient delay of tumor growth (Figures 6C, D).